Blogs
CAR-T reimbursement: Lessons learnt from NICE assessments
By Max Rex, Analyst Email: mrex@partners4access.com It’s been difficult to keep up with the flurry of reimbursement news coming out of England relating to the
NICE balks at Spinraza price, rejects reimbursement in its draft guidance
By Christina Poschen, Consultant Email: cposchen@partners4access.com Biogen’s Spinraza, a treatment for the rare genetic disease spinal muscular atrophy (SMA) is currently making headlines for its
Seven months to Brexit, does the biopharma industry have the tools to be ready?
Everything you need to know about the latest Brexit White Paper By Joanna Fernandes, Analyst Email: jfernandes@partners4access.com As the countdown to Brexit draws near, a
Slow Brexit proceedings frustrates biotech industry
By Aparna Krishnan, Corporate Affairs Lead As the UK Prime Minister’s office is preparing for the cabinet meeting at Chequers this Friday, British businesses including
Faster route to access in Scotland for rare disease patients requiring ultra-orphan drugs
By Alison Kneen, Vice President International Operations Fantastic news for Scottish patients who suffer from very rare diseases. As of October 1, 2018, patients will receive
Cancer diagnosis – a step forward for England
New rapid diagnostic and assessment centres are being piloted in ten areas across England in a focused approach to identify cancer early. These new centres
PRIME – two-year assessment – was it good for biopharma?
The PRIority Medicines Scheme (PRIME) of the European Medicines Agency (EMA) was started two years ago to support and optimise medicine development. The scheme provides early and
Irish patients continue to be denied vital new drugs
Todays’ article in the Irish Times[1] highlights again that patients in Ireland continue to be denied nine drugs which are already approved for use by
CDF to save NHS £140m over five years
The Cancer Drugs Fund (CDF) is expected to save the U.K. National Health Service (NHS) a minimum of £140 million over the next five years.
